Oncolytics Initiates Enrollment for Phase II Cancer Trial
Posted on: Monday, 9 June 2008, 06:00 CDT
Oncolytics Biotech has started patient enrollment in a Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.
This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of Reolysin given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.
The primary objective of the Phase II trial is to measure tumor responses and duration of response, and to describe any evidence of antitumor activity. The secondary objective is to determine the safety and tolerability of Reolysin when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination With Paclitaxel and Carboplatin
- Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
- Genta Initiates Phase 3 AGENDA Trial of Genasense for Patients With Advanced Melanoma; Randomized, Double-Blind Study Targets Biomarker-Defined Population
- Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients With Advanced Melanoma
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- Exelixis Reports Additional Data From a Phase I Trial of XL647 in Patients With Advanced Solid Tumors
- Palatin Technologies and King Pharmaceuticals Complete Enrollment in Two Phase IIb Clinical Trials Evaluating Bremelanotide in Patients With Erectile Dysfunction
- Researchers Find Chemotherapy and Radiation Together May Be Better for Patients with Locally Advanced Lung Cancer
- Targeted Genetics Announces Preliminary Results of Phase I Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
- A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer Patients
 |
 |
User Comments (0)
RSS Feeds